German biotech company Evotec said on Tuesday that it had entered into a drug discovery collaboration in metabolic diseases with U.S. drugmaker Eli Lilly. The total potential value of the collaboration, which will run for three years, is up to $1 billion. As part of the collaboration, Evotec will explore potential drug candidates for the treatment of diabetes and chronic liver disease, the Hamburg-based company said.
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.
Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.